.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The National Lung Screening Trial compared annual low-dose CT with chest radiography in adults at high risk for lung cancer. More than 53,000 participants were enrolled across U.S. centers, making this one of the landmark studies underpinning modern lung-cancer screening. The trial found a reduction in lung-cancer mortality with low-dose CT compared with chest radiography, supporting the principle that detecting disease at an earlier stage can translate into a survival benefit. For clinicians, the important lesson is not simply “screen with CT,” but “screen an appropriate high-risk population using a structured program.” Screening decisions depend on age, smoking exposure, eligibility criteria, follow-up of detected nodules and the ability to manage incidental findings and false positives. This aligns with the NAPCON lung-cancer and imaging themes and is particularly relevant to discussions about expanding access beyond major urban centers. The study remains influential because it demonstrated a mortality endpoint rather than only improved detection. In practice, the benefit of screening depends on appropriate patient selection, quality-assured imaging and access to downstream diagnostic and treatment services.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The National Lung Screening Trial compared annual low-dose CT with chest radiography in adults at high risk for lung cancer. More than 53,000 participants were enrolled across U.S. centers, making this one of the landmark studies underpinning modern lung-cancer screening. The trial found a reduction in lung-cancer mortality with low-dose CT compared with chest radiography, supporting the principle that detecting disease at an earlier stage can translate into a survival benefit. For clinicians, the important lesson is not simply “screen with CT,” but “screen an appropriate high-risk population using a structured program.” Screening decisions depend on age, smoking exposure, eligibility criteria, follow-up of detected nodules and the ability to manage incidental findings and false positives. This aligns with the NAPCON lung-cancer and imaging themes and is particularly relevant to discussions about expanding access beyond major urban centers. The study remains influential because it demonstrated a mortality endpoint rather than only improved detection. In practice, the benefit of screening depends on appropriate patient selection, quality-assured imaging and access to downstream diagnostic and treatment services.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
